| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,550 | 7,800 | 18.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.09. | WuXi XDC secures regulatory approval for Singapore site | 4 | Singapore Business Review | ||
| 21.09. | WuXi XDC Secures GMP Release for Singapore Manufacturing Site | 3 | Contract Pharma | ||
| 18.09. | WUXI XDC (02268): INTERIM REPORT 2026 | - | HKEx | ||
| 17.09. | WuXi XDC to Out-License Proprietary Payload-Linker Technology Platform to Ona Therapeutics | 1 | Contract Pharma | ||
| 28.08. | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 27.08. | WuXi XDC Cayman: Großaktionär plant Anteilsverkauf - Aktie gibt nach | 1 | Investing.com Deutsch | ||
| 25.08. | WuXi XDC H1 2026 slides: profit tops RMB 1bn, backlog hits $2bn | 5 | Investing.com | ||
| 25.08. | WuXi XDC: Gewinn im ersten Halbjahr 2026 übersteigt 1 Milliarde RMB - Aktie legt um 15 % zu | 1 | Investing.com Deutsch | ||
| WUXI XDC Aktie jetzt für 0€ handeln | |||||
| 25.08. | WUXI XDC (02268): GRANT OF RESTRICTED SHARES UNDER THE 2024 SHARE SCHEME | - | HKEx | ||
| 25.08. | WuXi XDC Aktie steigt nach starken Halbjahresergebnissen um fast 12 % | 1 | Investing.com Deutsch | ||
| 24.08. | WuXi XDC Cayman Inc. Profit Climbs In H1 | 1 | RTTNews | ||
| 24.08. | WUXI XDC (02268): INSIDE INFORMATION 2026 INTERIM RESULTS PRESENTATION | - | HKEx | ||
| 24.08. | WUXI XDC (02268): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 2 | HKEx | ||
| 14.07. | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 10.07. | WUXI XDC (02268): NOTICE OF BOARD MEETING | - | HKEx | ||
| 02.07. | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 26.06. | WUXI XDC (02268): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026 | - | HKEx | ||
| 26.06. | WUXI XDC (02268): CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING ... | - | HKEx | ||
| 17.06. | WUXI XDC (02268): CONNECTED TRANSACTION ENTERING INTO OF PROCESS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT | 1 | HKEx | ||
| 01.06. | WUXI XDC (02268): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 26, 2026 | - | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics (NDQ:TNGX): Its Pancreatic Cancer Data Was Extraordinary And Shares Have Tripled, But Are Investors Getting Ahead Of Themselves? | ||
| CG ONCOLOGY | 80,01 | +0,01 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| ERASCA | 13,780 | +0,15 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | +0,05 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 304,85 | -0,11 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| HARMONY BIOSCIENCES | 33,110 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Harmony Bio mit Kursziel von 55 Dollar | ||
| INHIBRX BIOSCIENCES | 69,06 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma | - Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;- 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 23,400 | 0,00 % | Rapport Therapeutics präsentiert Pipeline-Fortschritte und Phase-III-Fahrplan auf der Jefferies Global Healthcare Conference | ||
| RECURSION PHARMACEUTICALS | 2,820 | -0,18 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| ARRIVENT BIOPHARMA | 10,900 | 0,00 % | Guggenheim senkt Kursziel für ArriVent BioPharma auf $28 | ||
| COGENT BIOSCIENCES | 27,815 | +0,02 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| DYNE THERAPEUTICS | 15,880 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen |